Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -15.01% | -8.90% | |||
| Gross Profit | 26.84% | -28.09% | |||
| SG&A Expenses | 2.58% | 2.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.51% | -6.30% | |||
| Operating Income | 19.31% | -20.28% | |||
| Income Before Tax | 23.74% | -31.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.74% | -31.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.74% | -31.39% | |||
| EBIT | 19.31% | -20.28% | |||
| EBITDA | 19.53% | -20.67% | |||
| EPS Basic | 24.39% | -31.15% | |||
| Normalized Basic EPS | 24.37% | -31.14% | |||
| EPS Diluted | 24.39% | -31.15% | |||
| Normalized Diluted EPS | 24.37% | -31.14% | |||
| Average Basic Shares Outstanding | 0.84% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.84% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||